These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 28331043)

  • 21. Translating drug resistant tuberculosis treatment guidelines to reality in war-torn Kandahar, Afghanistan: A retrospective cohort study.
    Mesic A; Khan WH; Lenglet A; Lynen L; Ishaq S; Phyu EHH; Mar HT; Oraegbu A; Seddiq MK; Amirzada HK; Fernhout J; Kamau C; Ariti C; Gomez D; Decroo T
    PLoS One; 2020; 15(8):e0237787. PubMed ID: 32822375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct Detection by the Xpert MTB/RIF Assay and Characterization of Multi and Poly Drug-Resistant Tuberculosis in Guinea-Bissau, West Africa.
    Rabna P; Ramos J; Ponce G; Sanca L; Mané M; Armada A; Machado D; Vieira F; Gomes VF; Martins E; Colombatti R; Riccardi F; Perdigão J; Sotero J; Portugal I; Couto I; Atouguia J; Rodrigues A; Viveiros M
    PLoS One; 2015; 10(5):e0127536. PubMed ID: 26017968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis.
    Campbell JR; Falzon D; Mirzayev F; Jaramillo E; Migliori GB; Mitnick CD; Ndjeka N; Menzies D
    Emerg Infect Dis; 2020 Mar; 26(3):. PubMed ID: 31922953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
    Steingart KR; Schiller I; Horne DJ; Pai M; Boehme CC; Dendukuri N
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD009593. PubMed ID: 24448973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology of Drug-Resistant Tuberculosis.
    Dean AS; Cox H; Zignol M
    Adv Exp Med Biol; 2017; 1019():209-220. PubMed ID: 29116637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.
    Naz F; Ahmad N; Wahid A; Ahmad I; Khan A; Abubakar M; Khan SA; Khan A; Latif A; Ghafoor A
    BMC Infect Dis; 2021 Dec; 21(1):1209. PubMed ID: 34863099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Multidrug-resistant tuberculosis].
    Alcaide F; Santín M
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 13():54-60. PubMed ID: 19100168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan.
    Trauer JM; Achar J; Parpieva N; Khamraev A; Denholm JT; Falzon D; Jaramillo E; Mesic A; du Cros P; McBryde ES
    BMC Med; 2016 Nov; 14(1):187. PubMed ID: 27855693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
    PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB.
    Cox V; McKenna L; Acquah R; Reuter A; Wasserman S; Vambe D; Ustero P; Udwadia Z; Triviño-Duran L; Tommasi M; Skrahina A; Seddon JA; Rodolfo R; Rich M; Padanilam X; Oyewusi L; Ohler L; Lungu P; Loveday M; Khan U; Khan P; Hughes J; Hewison C; Guglielmetti L; Furin J
    Int J Tuberc Lung Dis; 2020 Nov; 24(11):1134-1144. PubMed ID: 33172520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Editorial: Updates from the World Health Organization (WHO) on Global Treatment Recommendations for Drug-Susceptible and Multidrug-Resistant Tuberculosis.
    Parums DV
    Med Sci Monit; 2021 Aug; 27():e934292. PubMed ID: 34366429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rifampicin Resistant Tuberculosis in Lesotho: Diagnosis, Treatment Initiation and Outcomes.
    Katende B; Esterhuizen TM; Dippenaar A; Warren RM
    Sci Rep; 2020 Feb; 10(1):1917. PubMed ID: 32024860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence-based Definition for Extensively Drug-Resistant Tuberculosis.
    Roelens M; Battista Migliori G; Rozanova L; Estill J; Campbell JR; Cegielski JP; Tiberi S; Palmero D; Fox GJ; Guglielmetti L; Sotgiu G; Brust JCM; Bang D; Lienhardt C; Lange C; Menzies D; Keiser O; Raviglione M
    Am J Respir Crit Care Med; 2021 Sep; 204(6):713-722. PubMed ID: 34107231
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
    Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
    BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
    Tembo BP; Malangu NG
    BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.